SynthesisFrontiers in medicine2026
MicroRNA regulation in pulmonary fibrosis: a bibliometric analysis of global research trends, collaborative networks, and emerging frontiers.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), is a progressive and fatal interstitial lung disease with limited treatment options. MicroRNAs (miRNAs) have emerged as critical regulators of fibrotic processes, yet a systematic overview of the research landscape in this rapidly growing field is lacking. Methods: We performed a comprehensive bibliometric analysis of publications on miRNA regulation in pulmonary fibrosis from January 1, 2000, to December 31, 2025, using the Web of Science Core Collection and Scopus databases. After deduplication, a total of 2,093 valid documents (articles and reviews) were analyzed. Multiple analytical tools-VOSviewer (v1.6.20), CiteSpace (v6.4R1), and the bibliometrix R package (v3.2.1)-were employed to examine annual publication trends, collaborative networks (countries, institutions, authors), co-citation clusters, citation bursts, journal dual-map overlays, and keyword evolution. Results: The annual publication output increased steadily from 2007 to 2021, peaking at 229 papers, then stabilized at 150-193 papers per year (2022-2025). China (889 papers, 38.4%) and the United States (477 papers, 20.6%) were the most productive countries, although United States and European papers exhibited higher average citation impact (United States: 74.79; Germany: 86.49) compared to China (29.28). Nanjing Medical University (43 papers) and the University of Pittsburgh (28 papers) were leading institutions. Author productivity followed Lotka's Law, with 89.6% of authors publishing only one paper. Co-citation network analysis (1,108 nodes, Conclusion: This bibliometric analysis provides a systematic mapping of the global research landscape on miRNA regulation in pulmonary fibrosis over the past 26 years. The field has evolved from basic molecular mechanisms toward emerging frontiers including extracellular vesicle-based communication, circular RNAs, and cellular senescence. These findings serve as a valuable resource for researchers seeking to understand current trends, collaborative networks, and future directions in miRNA-targeted pulmonary fibrosis research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.